Good Life Advisors’s Atossa Therapeutics ATOS Stock Holding History

Good Life Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-113	Closed	-$8K	–	235
2018 Q1	$8K	Hold	113	–	–	﹤0.01%	217
2017 Q4	$6K	Hold	113	–	–	﹤0.01%	234
2017 Q3	$10K	Buy	+113	New	+$8.97K	﹤0.01%	216

Other funds holding ATOS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Good Life Advisors's ATOS Position: Q2 2018 in Review

Good Life Advisors sold out of Atossa Therapeutics (ATOS) in Q2 2018, closing a stake of 113 shares — an estimated $8K sold.

Good Life Advisors first reported a position in ATOS in Q3 2017 and held it in 3 quarters. The position peaked at $10K in Q3 2017. 14 funds tracked by Wall St. Rank hold ATOS as of Q2 2018.

Good Life Advisors reported no remaining Atossa Therapeutics position as of Q2 2018 after selling out during the quarter.
Good Life Advisors sold 113 Atossa Therapeutics shares in Q2 2018, an estimated $8K.
Good Life Advisors first reported a position in Atossa Therapeutics in Q3 2017 and held it in 3 quarters.
Good Life Advisors's Atossa Therapeutics position peaked at $10K in Q3 2017.
14 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2018.

Based on Good Life Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.